CNS Drugs

, Volume 17, Issue 5, pp 325–342 | Cite as

The Role of Hormones and Hormonal Treatments in Premenstrual Syndrome

  • Torbjörn Bäckström
  • Lotta Andreen
  • Vita Birzniece
  • Inger Björn
  • Inga-Maj Johansson
  • Maud Nordenstam-Haghjo
  • Sigrid Nyberg
  • Inger Sundström-Poromaa
  • Göran Wahlström
  • Mingde Wang
  • Di Zhu
Review Article

Abstract

Premenstrual syndrome (PMS) is a menstrual cycle-linked condition with both mental and physical symptoms. Most women of fertile age experience cyclical changes but consider them normal and not requiring treatment. Up to 30% of women feel a need for treatment. The aetiology is still unclear, but sex steroids produced by the corpus luteum of the ovary are thought to be symptom provoking, as the cyclicity disappears in anovulatory cycles when a corpus luteum is not formed. Progestogens and progesterone together with estrogen are able to induce similar symptoms as seen in PMS. Symptom severity is sensitive to the dosage of estrogen. The response systems within the brain known to be involved in PMS symptoms are the serotonin and GABA systems. Progesterone metabolites, especially allopregnanolone, are neuroactive, acting via the GABA system in the brain. Allopregnanolone has similar effects as benzodiazepines, barbiturates and alcohol; all these substances are known to induce adverse mood effects at low osages in humans and animals. SSRIs and substances inhibiting ovulation, such as gonadotrophin-releasing hormone (GnRH) agonists, have proven to be effective treatments. To avoid adverse effects when high dosages of GnRH agonists are sed, add-back hormone replacement therapy is recommended. Spironolactone also has a beneficial effect, although not as much as SSRIs and GnRH agonists

References

  1. 1.
    Sveindottir H, Bäckström T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79: 405–13PubMedCrossRefGoogle Scholar
  2. 2.
    Halbreich U, Bancroft J, Dennerstein L, et al. Menstrually related disorders: points of consensus, debate, and disagreement. Neuropsychopharmacology 1993; 9: 13–5PubMedGoogle Scholar
  3. 3.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 714–8Google Scholar
  4. 4.
    Hammarbäck S, Bäckström T, MacGibbon-Taylor B. Diagnosis of premenstrual syndrome: description and evaluation of a procedure for diagnosis and differential diagnosis. J Psychosom Obstet Gynaecol 1989; 10: 25–42CrossRefGoogle Scholar
  5. 5.
    Andersch B, Wendestam C, Hahn L, et al. Premenstrual complaints. I: prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obset Gynaecol 1986; 5: 39–49Google Scholar
  6. 6.
    Sternfeld B, Swindle R, Chawla A, et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002; 99: 1014–24PubMedCrossRefGoogle Scholar
  7. 7.
    Sveinsdottir H, Marteinsdottir G. Retrospective assessment of premenstrual changes in Icelandic women. Health Care Women Int 1991; 12: 303–15PubMedCrossRefGoogle Scholar
  8. 8.
    Sveinsdottir H, Lundman B, Norberg A. Women’s perceptions of phenomena they label premenstrual tension: normal experiences reflecting ordinary behaviour. J Adv Nurs 1999; 30: 916–25PubMedCrossRefGoogle Scholar
  9. 9.
    Marvan ML, Cortes-Iniestra S. Women’s beliefs about the prevalence of premenstrual syndrome and biases in recall of premenstrual changes. Health Psychol 2001; 20: 276–80PubMedCrossRefGoogle Scholar
  10. 10.
    Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I: prevalence, natural history and help-seeking behavior. J Reprod Med 1988; 33: 340–6Google Scholar
  11. 11.
    Ramcharan S, Love EJ, Fick GH, et al. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 1992; 45: 377–92PubMedCrossRefGoogle Scholar
  12. 12.
    Angst J, Sellaro R, Merikangas KR, et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6PubMedCrossRefGoogle Scholar
  13. 13.
    Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147: 1634–3PubMedGoogle Scholar
  14. 14.
    Hardie EA. Prevalence and predictors of cyclic and noncyclic affective change. Psychol Women Q 1997; 21: 229–314CrossRefGoogle Scholar
  15. 15.
    Gehlert S, Hartlage S. A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 1997; 18: 36–44PubMedCrossRefGoogle Scholar
  16. 16.
    Banerjee N, Roy KK, Takkar D. Premenstrual dysphoric disorder: a study from India. Int J Fertil Womens Med 2000; 45: 342–4PubMedGoogle Scholar
  17. 17.
    Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32PubMedCrossRefGoogle Scholar
  18. 18.
    Singh BB, Berman BM, Simpson RL, et al. Incidence of premenstrual syndrome and remedy usage: a national probability sample study. Altern Ther Health Med 1998; 4: 75–9PubMedGoogle Scholar
  19. 19.
    Bäckström T, Sanders D, Leask RM, et al. Mood, sexuality, hormones and the menstrual cycle. II: hormone levels and their relationship to premenstrual syndrome. Psychsom Med 1983; 45: 503–7Google Scholar
  20. 20.
    Schmidt PJ, Nieman LK, Grover GN, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 1991; 324: 1174–9PubMedCrossRefGoogle Scholar
  21. 21.
    Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158: 5–11PubMedGoogle Scholar
  22. 22.
    Wang M, Bäckström T, Sundström I, et al. Neuroactive steroids and central nervous system disorders. Int Rev Neurobiol 2001: 46: 421–59PubMedCrossRefGoogle Scholar
  23. 23.
    Hammarbäck S, Ekholm UB, Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 1991; 125: 132–7Google Scholar
  24. 24.
    Hamarbäck S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67: 159–66CrossRefGoogle Scholar
  25. 25.
    Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779–86PubMedGoogle Scholar
  26. 26.
    Mezrow G, Shoupe D, Spicer D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62: 932–7PubMedGoogle Scholar
  27. 27.
    Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 72: 252A-FCrossRefGoogle Scholar
  28. 28.
    Hammarbäck S, Bäckström T, Holst J, et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestogen postmenopausal replacement treatment. Acta Obstet Gynecol Scand 1985; 64: 393–7PubMedCrossRefGoogle Scholar
  29. 29.
    Magos AL, Brewster E, Sing R, et al. The effect of norethisterone in postmenopausal women on oestrogen therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986; 93: 1290–6PubMedCrossRefGoogle Scholar
  30. 30.
    Björn I, Bixo M, Strandberg-Nöjd K, et al. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000; 183: 1419–26PubMedCrossRefGoogle Scholar
  31. 31.
    Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338: 209–16PubMedCrossRefGoogle Scholar
  32. 32.
    Hammarbäck S, Damber JE, Bäckström T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989; 68: 125–30PubMedCrossRefGoogle Scholar
  33. 33.
    Seippel L, Bäckström T. Luteal phase estradiol relates to symptom severity between patients with premenstrual syndrome. J Clin Endocrinol Metab 1998; 83: 1988–92PubMedCrossRefGoogle Scholar
  34. 34.
    Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990; 15: 489–93PubMedCrossRefGoogle Scholar
  35. 35.
    Klaiber EL, Broverman DM, Vogel W, et al. Relationships of serum estradiol levels, menopausal duration and mood during hormonal replacement therapy. Psychoneuroendocrinology 1997; 22: 549–58PubMedCrossRefGoogle Scholar
  36. 36.
    Björn I, Sundsröm-Poromaa I, Bixo M, et al. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocr Metab. In pressGoogle Scholar
  37. 37.
    Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double blind comparison with placebo. Acta Psychiatr Scand Suppl 1972; 236: 1–84PubMedGoogle Scholar
  38. 38.
    Graham CA, Sherwin BB. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J Psychosom Res 1987; 31: 45–53PubMedCrossRefGoogle Scholar
  39. 39.
    Sundström I, Andersson A, Nyberg S, et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67: 126–38PubMedCrossRefGoogle Scholar
  40. 40.
    Sundström I, Ashbrook D, Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997; 22: 25–38PubMedCrossRefGoogle Scholar
  41. 41.
    Sundström I, Nyberg S, Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997; 17: 370–81PubMedCrossRefGoogle Scholar
  42. 42.
    Nyberg S, Sundström Poromaa I, Bäckström T. Patients with premenstrual dysphoric disorder have a decreased sensitivity to alcohol in the luteal phase [abstract no. 187]. Nordic Federation of Societies of Obstetricians and Gynecologists (NFOG) XXXIII Congress; 2002 Jun 1–4; Umea. Umea: Nordic Federation of Societies of Obstetricians and Gynecologists, 2002Google Scholar
  43. 43.
    Schmidt PJ, Purdy RH, Moore PH, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79: 1256–60PubMedCrossRefGoogle Scholar
  44. 44.
    Wang MD, Seippel L, Purdy RH, et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnan-3,20-dione and 3α-hydrox-y-5α-pregnan-20-one. J Clin Endocrinol Metab 1996; 81: 1076–82PubMedCrossRefGoogle Scholar
  45. 45.
    Sundström I, Bäckström T. Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects. Biol Psychiatry 1998; 44: 755–64PubMedCrossRefGoogle Scholar
  46. 46.
    Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709–14PubMedCrossRefGoogle Scholar
  47. 47.
    Monteleone P, Luisi S, Tonetti A, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000; 142: 269–73PubMedCrossRefGoogle Scholar
  48. 48.
    McEwen BS, Coirini H, Schumacher M. Steroid effects on neuronal activity: when is the genome involved? Ciba Found Symp 1990; 153: 3–12PubMedGoogle Scholar
  49. 49.
    Chan AF, Mortola JF, Wood SH, et al. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994; 84: 1001–5PubMedGoogle Scholar
  50. 50.
    Kouri EM, Halbreich U. State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol Bull 1997; 33: 767–70PubMedGoogle Scholar
  51. 51.
    Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32: 37–44PubMedCrossRefGoogle Scholar
  52. 52.
    Bixo M, Allard P, Bäckström T, et al. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology 2001; 26: 551–64PubMedCrossRefGoogle Scholar
  53. 53.
    Sundström Poromaa I, Wihlbäck A-C, BixoM, et al. Influence of menstrual cycle on platelet serotonin uptake site and 5-HT2A receptor binding [abstract no. 32]. Nordic Federation of Societies of Obstetricians and Gynecologists (NFOG) XX–XIII Congress; 2002 Jun 1–4; Umea. Umea: Nordic Federation of Societies of Obstetricians and Gynecologists, 2002Google Scholar
  54. 54.
    Sibille E, Pavlides C, Benke D,et al. Genetic inactivation of the serotoninla receptor in mice results in downregulation of major GABAA receptor a subunits, reduction of GABAA receptor binding, and benzodiazepine-resistant anxiety. J Neurosci 2000; 20: 2758–65PubMedGoogle Scholar
  55. 55.
    Sundström I, Bäckström T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 1998; 23: 73–88PubMedCrossRefGoogle Scholar
  56. 56.
    Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992; 6: 2311–22PubMedGoogle Scholar
  57. 57.
    Bäckström T, Gee KW, Lan N, et al. Steroids in relation to epilepsy and anaesthesia. Ciba Found Symp 1990; 153: 225–30PubMedGoogle Scholar
  58. 58.
    Beauchamp MH, Ormerod BK, Jhamandas K, et al. Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. Pharmacol Biochem Behav 2000; 67: 29–35PubMedCrossRefGoogle Scholar
  59. 59.
    Fish EW, Faccidomo S, DeBold JF, et al. Alcohol, allopregnanolone and aggression in mice. Psychopharmacology (Berl) 2001; 153: 473–83CrossRefGoogle Scholar
  60. 60.
    Lee GP, Loring DW, Meador KJ, et al. Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion. Neurology 1988; 38: 1233–6PubMedCrossRefGoogle Scholar
  61. 61.
    Kurthen M, Linke DB, Reuter BM, et al. Severe negative emotional reactions in intracarotid sodium amytal procedures: further evidence for hemispheric asymmetries? Cortex 1991; 27: 333–7PubMedGoogle Scholar
  62. 62.
    Masia SL, Perrine K, Westbrook L, et al. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. Neurology 2000; 54: 1691–3PubMedCrossRefGoogle Scholar
  63. 63.
    Miczek KA, O’Donnell JM. Alcohol and chlordiazepoxide increase suppressed aggression in mice. Psychopharmacology 1980; 69: 39–44PubMedCrossRefGoogle Scholar
  64. 64.
    Miczek KA, Weerts EM, DeBold JF. Alcohol, benzodiazepine-GABAA receptor complex and aggression: ethological analysis of individual differences in rodents and primates. J Stud Alcohol Suppl 1993; 11: 170–179PubMedGoogle Scholar
  65. 65.
    Yoshimura H, Ogawa N. Acute and chronic effects of psychotropic drugs on maternal aggression in mice. Psychopharmacology 1989; 97: 339–42PubMedCrossRefGoogle Scholar
  66. 66.
    Ferrari PF, Parmigiani S, Rodgers RJ, et al. Differential effects of chlordiazepoxide on aggressive behavior in male mice: the influence of social factors. Psychopharmacology (Berl) 1997; 134: 258–65CrossRefGoogle Scholar
  67. 67.
    Miczek KA, DeBold JF, van Erp AM, et al. Alcohol, GABAA-benzodiazepine receptor complex, and aggression. Recent Dev Alcohol 1997; 13: 139–71PubMedCrossRefGoogle Scholar
  68. 68.
    Björn I, Bixo M, Nöjd K, et al. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol Endocrinol 2002; 16: 1–8PubMedGoogle Scholar
  69. 69.
    Andréen L, Bixo M, Nyberg S, et al. Progesterone effects during sequential hormone replacement therapy. Eur J Endocrinology. In pressGoogle Scholar
  70. 70.
    Gulinello M, Gong QH, Li X, et al. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res 2001; 910: 55–66PubMedCrossRefGoogle Scholar
  71. 71.
    Birzniece V, Zhu D, Lindblad C, et al. Acute allopregnanolone tolerance [abstract no. 186]. Nordic Federation of Societies of Obstetricians and Gynecologists (NFOG) XXXIII Congress; 2002 Jun 1–4; Umea. Umea: Nordic Federation of Societies of Obstetricians and Gynecologists, 2002Google Scholar
  72. 72.
    Bäckström T, Baird DT, Bancroft J, et al. Endocrinological aspects of cyclical mood changes during the menstrual cycle or the premenstrual syndrome. J Psychosom Obstet Gynaecol 1983; 2: 8–20CrossRefGoogle Scholar
  73. 73.
    Banerjee PK, Snead III OC. Neuroactive steroids exacerbate gamma-hydroxybutyric acid-induced absence seizures in rats. Eur J Pharmacol 1998; 359: 41–8PubMedCrossRefGoogle Scholar
  74. 74.
    Grunewald RA, Aliberti V, Panayiotopoulos CP. Exacerbation of typical absence seizures by progesterone. Seizure 1992; 1: 137–8PubMedCrossRefGoogle Scholar
  75. 75.
    Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356: 1131–6PubMedCrossRefGoogle Scholar
  76. 76.
    Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12: 167–76PubMedCrossRefGoogle Scholar
  77. 77.
    Steiner M, Steinberg S, Stewart S, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332: 1529–34PubMedCrossRefGoogle Scholar
  78. 78.
    Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993; 9: 133–45PubMedGoogle Scholar
  79. 79.
    Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994; 55: 332–5PubMedGoogle Scholar
  80. 80.
    Sundström-Poromaa I, Bixo M, Björn I, et al. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. Psychosom Obstet Gynecol 2000; 21: 205–11CrossRefGoogle Scholar
  81. 81.
    Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. BMJ 1986; 292: 1629–33PubMedCrossRefGoogle Scholar
  82. 82.
    Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20: 193–209PubMedCrossRefGoogle Scholar
  83. 83.
    Bäckström CT, Boyle H, Baird DT. Persistence of symptoms of premenstrual tension in hysterectomized women. Br J Obstet Gynaecol 1981; 88: 530–6PubMedCrossRefGoogle Scholar
  84. 84.
    Muse KN, Cetel NS, Futterman LA, et al. The premenstrual syndrome: effects of “medical ovariectomy”. N Engl J Med 1984; 311: 1345–9PubMedCrossRefGoogle Scholar
  85. 85.
    Bancroft J, Boyle H, Warner P, et al. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol (Oxf) 1987; 27: 171–82CrossRefGoogle Scholar
  86. 86.
    Hussain SY, Massil JH, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992; 6: 57–64PubMedCrossRefGoogle Scholar
  87. 87.
    Freeman EW, Sondheimer SJ, Rickels K, et al. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. J Clin Psychiatry 1993; 54: 192–5PubMedGoogle Scholar
  88. 88.
    West CP, Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 1994; 9: 1058–63PubMedGoogle Scholar
  89. 89.
    Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33: 303–9PubMedGoogle Scholar
  90. 90.
    Leather AT, Stud JW, Watson NR, et al. The treatment of severe premenstrual syndrome with goserelin with and without “add-back” estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 1999; 13: 48–55PubMedCrossRefGoogle Scholar
  91. 91.
    Di Carlo C, Palomba S, Tommaselli GA, et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001; 75: 380–4PubMedCrossRefGoogle Scholar
  92. 92.
    Helvacioglu A, Yeoman RR, Hazelton JM, et al. Premenstrual syndrome and related hormonal changes: long-acting gonadotropin releasing hormone agonist treatment. J Reprod Med 1993; 38: 864–70PubMedGoogle Scholar
  93. 93.
    Studd J, Leather AT. The need for add-back with a gonadotropin-releasing hormone agonist therapy. Br J Obstet Gynaecol 1996; 103: 1–4PubMedCrossRefGoogle Scholar
  94. 94.
    Sundström I, Nyberg S, Bixo M, et al. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999; 78: 891–9PubMedCrossRefGoogle Scholar
  95. 95.
    Magos AL, Collins WP, Studd JW. Management of the premenstrual syndrome by subcutaneous implants of oestradiol. J Psychosom Obstet Gynaecol 1984; 3: 93–9CrossRefGoogle Scholar
  96. 96.
    Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; II: 730–2CrossRefGoogle Scholar
  97. 97.
    Smith RN, Studd JW, Zamblera D, et al. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475–84PubMedCrossRefGoogle Scholar
  98. 98.
    Watson NR, Studd JW, Savvas M, et al. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 1990; 4: 99–107PubMedCrossRefGoogle Scholar
  99. 99.
    West CP. Inhibition of ovulation with oral progestins: effectiveness in premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 1990; 34: 119–28PubMedCrossRefGoogle Scholar
  100. 100.
    Gilmore DH, Hawthorn RJ, Hart DM. Danol for premenstrual syndrome: a preliminary report of a placebo-controlled double-blind study. J Int Med Res 1985; 13: 129–30PubMedGoogle Scholar
  101. 101.
    Watts JF, Edwards RL, Butt WR. Treatment of premenstrual syndrome using danazol: preliminary report of a placebo-controlled, double-blind, dose ranging study. J Int Med Res 1985; 13: 127–8PubMedGoogle Scholar
  102. 102.
    Deeny M, Hawthorn R, McKay Hart D. Low dose danazol in the treatment of the premenstrual syndrome. Postgrad Med J 1991; 67: 450–4PubMedCrossRefGoogle Scholar
  103. 103.
    Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril 1991; 56: 1066–9PubMedGoogle Scholar
  104. 104.
    O’Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol 1999; 180: 18–23PubMedCrossRefGoogle Scholar
  105. 105.
    Casson P, Hahn PM, Van Vugt DA, et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 99–105PubMedGoogle Scholar
  106. 106.
    Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 105–9PubMedGoogle Scholar
  107. 107.
    Milsom I, Sundell G, Andersch B. A longitudinal study of contraception and pregnancy outcome in a representative sample of young Swedish women. Contraception 1991; 43: 111–9PubMedCrossRefGoogle Scholar
  108. 108.
    Sanders SA, Graham CA, Bass JL, et al. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001; 64: 51–8PubMedCrossRefGoogle Scholar
  109. 109.
    Walker A, Bancroft J. Relationship between premenstrual symptoms and oral contraceptive use: a controlled study. Psychosom Med 1990; 52: 86–96PubMedGoogle Scholar
  110. 110.
    Bäckström T, Lindhe BÅ, Cavalli-Björkman B, et al. Effects of oral contraceptives on mood: a randomized comparison of three phasic and monophasic preparations. Contraception 1992; 46: 253–68PubMedCrossRefGoogle Scholar
  111. 111.
    Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36: 257–66PubMedCrossRefGoogle Scholar
  112. 112.
    Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993; 37: 195–202PubMedCrossRefGoogle Scholar
  113. 113.
    Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561–9PubMedCrossRefGoogle Scholar
  114. 114.
    Andersch B. The effect of various oral contraceptive combinations on premenstrual symptoms. Int J Gynaecol Obstet 1982; 20: 463–9PubMedCrossRefGoogle Scholar
  115. 115.
    Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124–34PubMedCrossRefGoogle Scholar
  116. 116.
    Bancroft J, Sanders D, Warner P, et al. The effects of oral contraceptives on mood and sexuality: comparison of triphasic and combined preparations. J Psychosom Obstet and Gynaecol 1987; 7: 1–8CrossRefGoogle Scholar
  117. 117.
    Barrington JW, Bowen Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997; 104: 614–6PubMedCrossRefGoogle Scholar
  118. 118.
    Wagner KD, Berenson AB. Norplant-associated major depression and panic disorder. J Clin Psychiatry 1994; 55: 478–80PubMedGoogle Scholar
  119. 119.
    Selye H, Mecs I, Savoie L. Inhibition of anesthetics and sedative actions by spironolactone. Anesthesiology 1969; 31: 261–4PubMedCrossRefGoogle Scholar
  120. 120.
    Selye H. Spironolactone actions, independent of mineralocorticoid blockade. Steroids 1969; 13: 803–8PubMedCrossRefGoogle Scholar
  121. 121.
    Wang M, Hamarbäck S, Lindhe BA, et al. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74: 803–8PubMedCrossRefGoogle Scholar
  122. 122.
    O’Brien PMS, Craven D, Selby C, et al. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynecol 1979; 86: 142–7CrossRefGoogle Scholar
  123. 123.
    Hendler NH. Spironolactone for premenstrual syndrome. Female Patient 1980; 5: 17–20Google Scholar
  124. 124.
    Hellberg D, Claesson B, Nilsson S. Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynaecol Obstet 1991; 34: 243–8PubMedCrossRefGoogle Scholar
  125. 125.
    Vellacott ID, Shroff NE, Pearce MY, et al. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 1987; 10: 450–6PubMedCrossRefGoogle Scholar
  126. 126.
    Burnet RB, Radden HS, Easterbrook EG, et al. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 1991; 31: 366–8PubMedCrossRefGoogle Scholar
  127. 127.
    Vellacott I. D, O’Brien PM. Effect of spironolactone on premenstrual syndrome symptoms. J Reprod Med 1987; 32: 429–34Google Scholar
  128. 128.
    Dalton K. The premenstrual syndrome and progesterone therapy. London: William Heineman, 1984Google Scholar
  129. 129.
    De Lignieres B, Dennerstein L, Bäckström T. Influence of route of administration on progesterone metabolism. Maturitas 1995; 21: 251–7PubMedCrossRefGoogle Scholar
  130. 130.
    Maddocks S, Hahn P, Moller F, et al. A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am J Obstet Gynecol 1986; 154: 573–81PubMedGoogle Scholar
  131. 131.
    Andersch B, Hahn L. Progesterone treatment of premenstrual tension: a double blind study. J Psychosom Res 1985; 29: 489–93PubMedCrossRefGoogle Scholar
  132. 132.
    Freeman E, Rickels K, Sondheimer SJ, et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA 1990; 264: 349–53PubMedCrossRefGoogle Scholar
  133. 133.
    Sampson GA. Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br J Psychiatry 1979: 135: 209–15PubMedCrossRefGoogle Scholar
  134. 134.
    Magos A, Studd J. Progesterone and the premenstrual syndrome: a double blind crossover trial. BMJ (Clin Res Ed) 1985; 291: 213–4CrossRefGoogle Scholar
  135. 135.
    Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome: Progesterone Study Group. Br J Gen Pract 1995; 45: 589–93PubMedGoogle Scholar
  136. 136.
    Baker ER, Best RG, Manfredi RL, et al. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. J Assist Reprod Genet 1995; 12: 205–9PubMedCrossRefGoogle Scholar
  137. 137.
    Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 1991; 561: 157–61PubMedCrossRefGoogle Scholar
  138. 138.
    Wieland S, Lan NC, Mirasedeghi S, et al. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-o1-20-one. Brain Res 1991; 565: 263–8PubMedCrossRefGoogle Scholar
  139. 139.
    Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274: 51–7PubMedCrossRefGoogle Scholar
  140. 140.
    Dennerstein L, Spencer-Gardner L, Gotts C, et al. Progesterone and the premenstrual syndrome: a double blind crossover trial. MJ 1985; 290: 1617–21CrossRefGoogle Scholar
  141. 141.
    Vanselow W, Dennerstein L, Greenwood KM, et al. Effect of progesterone and its 5α- and 5β-metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996; 17: 29–38PubMedCrossRefGoogle Scholar
  142. 142.
    Freeman EW, Purdy RH, Coutifaris C, et al. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993; 58: 478–84PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Torbjörn Bäckström
    • 1
  • Lotta Andreen
    • 1
  • Vita Birzniece
    • 1
  • Inger Björn
    • 1
  • Inga-Maj Johansson
    • 1
  • Maud Nordenstam-Haghjo
    • 1
  • Sigrid Nyberg
    • 1
  • Inger Sundström-Poromaa
    • 1
  • Göran Wahlström
    • 1
  • Mingde Wang
    • 1
  • Di Zhu
    • 1
  1. 1.Department of Clinical Sciences, Obstetrics and GynecologyUmeå UniversityUmeåSweden

Personalised recommendations